Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc. (FNCH): 4 pipeline candidates · ~12 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
11.7 months
D/E 2.21 · 0% dilution
Lead: Preclinical
4 candidates
N/A
N/A
A transparent, data-derived signal for Finch Therapeutics Group, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$10.7M
Cash
$18.4M
Quarterly Burn
$4.7M
Runway
11.7 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in Finch Therapeutics Group, Inc.'s pipeline?
Finch Therapeutics Group, Inc. (FNCH) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Finch Therapeutics Group, Inc.'s lead drug candidate?
Finch Therapeutics Group, Inc.'s most advanced tracked candidate is cp101 (Preclinical) for recurrent C. difficile infection.
What is Finch Therapeutics Group, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Finch Therapeutics Group, Inc. has approximately 11.7 months of cash runway.
What is Finch Therapeutics Group, Inc.'s market capitalization?
Finch Therapeutics Group, Inc.'s market capitalization is approximately $10.7M.
Who is the CEO of Finch Therapeutics Group, Inc.?
Mr. Matthew P. Blischak J.D. is the chief executive officer of Finch Therapeutics Group, Inc. (FNCH).
Get the full picture on Finch Therapeutics Group, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.